Literature DB >> 8352186

Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery.

J Skoularigis1, C Röthlisberger, D Skudicky, M R Essop, T Wisenbaugh, P Sareli.   

Abstract

Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone. Protocol included high loading dosages of amiodarone for 4 weeks, and if conversion to sinus rhythm (SR) was not achieved then electrical cardioversion was performed. Patients converted to SR were maintained on low-dose amiodarone for another 4 weeks when treatment was discontinued. Overall, 23 patients (77%) converted to SR after 4 weeks of therapy: 12 (40%) taking amiodarone alone and 11 (37%) with the addition of electrical cardioversion. The duration of AF > 48 months was an adverse factor in the ability to restore SR. Sixteen patients (70%) remained in SR at a mean follow-up of 17 months. The duration of AF < or = 48 months alone or in combination with left atrial diameter < or = 45 mm were the best predictors for long-term maintenance of SR. Thus, short-term amiodarone with or without electrical cardioversion is effective and safe in the treatment of chronic rheumatic AF after mitral valve surgery. The duration of AF and left atrial size can be used to identify patients with successful outcome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352186     DOI: 10.1016/0002-9149(93)91134-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  The outcome of direct current cardioversion (DCC) for the treatment of atrial fibrillation (AF) in a district general hospital in Ireland.

Authors:  K P O'Rourke; C Cotter; D Mullane; P Thorpe; P Sullivan
Journal:  Ir J Med Sci       Date:  2006 Apr-Jun       Impact factor: 1.568

Review 2.  Atrial tachyarrhythmia after cardiac surgery.

Authors:  K H Stricker; H U Rothen; J Fuhrer
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

Review 3.  Current Perspectives: Rheumatic Atrial Fibrillation.

Authors:  Bhima Shankar P R; Hygriv Roa B; S Jaishankar; M Narasimhan
Journal:  J Atr Fibrillation       Date:  2010-03-01

4.  Efficacy of a new balloon catheter for internal cardioversion of chronic atrial fibrillation without anaesthesia.

Authors:  E Alt; R Ammer; G Lehmann; C Schmitt; J Pasquantonio; A Schömig
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

5.  Comparison of the effects of bepridil and aprindine for the prevention of atrial fibrillation after cardiac and aortic surgery: A prospective randomized study.

Authors:  Mahito Ozawa; Takashi Komatsu; Yoshihiro Sato; Fusanori Kunugita; Hideaki Tachibana; Atsushi Tashiro; Hitoshi Okabayashi; Motoyuki Nakamura
Journal:  J Arrhythm       Date:  2015-05-16

6.  A randomized placebo-controlled trial with amiodarone for persistent atrial fibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty.

Authors:  Vinoth Kumar Vilvanathan; Budunur C Srinivas Prabhavathi Bhat; Manjunath Cholenahally Nanjappa; Bharathi Pandian; Vithal Bagi; Sridhar Kasturi; Shiva Kumar Bandimida
Journal:  Indian Heart J       Date:  2016-04-20

7.  Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients: Ibutilide with magnesium for chemical cardioversion of atrial fibrillation or flutter.

Authors:  Amit Malviya; Manish Kapoor; Rondeep Kumar Nath Sivam; Shakeel Ahamad Khan; Ruchi Pandey; Utpal Kumar; Tony Ete; Animesh Mishra
Journal:  Indian Heart J       Date:  2020-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.